{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.7","value":"-28.5"},{"groupId":"OG001","value":"-45.0"},{"groupId":"OG002","value":"-20.0"},{"groupId":"OG003","value":"-21.0"},{"groupId":"OG004","spread":"16.3","value":"-22.5"},{"groupId":"OG005","spread":"10.8","value":"-29.0"},{"groupId":"OG006","spread":"12.","value":"-12.0"}]}],"title":"Systolic blood pressure"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.2","value":"-19.5"},{"groupId":"OG001","value":"-27.0"},{"groupId":"OG002","value":"-20.0"},{"groupId":"OG003","value":"-25.0"},{"groupId":"OG004","spread":"7.8","value":"-8.5"},{"groupId":"OG005","spread":"5.5","value":"-14.3"},{"groupId":"OG006","spread":"4.2","value":"-10.0"}]}],"title":"Diastolic blood pressure"}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"2"}],"units":"Participants"}],"description":"Minimum change from baseline is defined for each participant as the minimum change from baseline value observed across all visits.","dispersionType":"Standard Deviation","groups":[{"description":"Ganitumab 20 mg/kg once every 4 weeks by intravenous infusion.","id":"OG000","title":"20050118: Ganitumab 20 mg/kg"},{"description":"Conatumumab 0.45 mg/kg every 2 weeks by intravenous infusion.","id":"OG001","title":"20050171: Conatumumab 0.45 mg/kg"},{"description":"Conatumumab 3 mg/kg every 3 weeks by intravenous infusion.","id":"OG002","title":"20060295: Conatumumab 3 mg/kg"},{"description":"Conatumumab 5 mg/kg once every 3 weeks by intravenous infusion.","id":"OG003","title":"20060340: Conatumumab 5 mg/kg"},{"description":"Conatumumab 2 mg/kg once every 2 weeks by intravenous infusion in addition to modified FOLFOX6 chemotherapy and bevacizumab 5 mg/kg once every 2 weeks.","id":"OG004","title":"20060464: Conatumumab 2 mg/kg + mFOLFOX6 + Bevacizumab"},{"description":"Conatumumab 10 mg/kg once every 2 weeks by intravenous infusion in addition to modified FOLFOX6 chemotherapy, with or without bevacizumab 5 mg/kg once every 2 weeks.","id":"OG005","title":"20060464: Conatumumab 10 mg/kg + mFOLFOX6 ± Bevacizumab"},{"description":"Conatumumab 15 mg/kg + ganitumab 18 mg/kg once every 3 weeks by intravenous infusion.","id":"OG006","title":"20070411: Conatumumab 15 mg/kg + Ganitumab 18 mg/kg"}],"paramType":"MEAN","populationDescription":"Participants who received at least one dose of conatumumab or ganitumab.","reportingStatus":"POSTED","timeFrame":"Baseline and day 1 of each treatment cycle (every 2, 3, or 4 weeks depending on dosing schedule) up to 30 days after last dose; median duration of treatment with conatumumab was 1190.5 days and 1163.0 days for ganitumab.","title":"Minimum Change From Baseline in Blood Pressure","type":"SECONDARY","unitOfMeasure":"mmHg"}